Journal
DIGESTION
Volume 86, Issue -, Pages 45-54Publisher
KARGER
DOI: 10.1159/000341941
Keywords
Pregnancy; Breastfeeding; Medical therapy benefits
Categories
Funding
- Swiss National Science Foundation [320000-114009/3, 32473B_135694/1]
- Zurich Center for Integrative Human Physiology of the University of Zurich
- Swiss IBD Cohort [3347CO-108792]
- Swiss National Science Foundation (SNF) [32473B_135694] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Inflammatory bowel disease (IBD) is frequent in women during their peak reproductive years. Accordingly, a significant number of questions and uncertainties arise from this population regarding the risk of transmission of IBD to the offspring, the impact of the disease and therapies on the fertility, the role of the disease on the course of the pregnancy and the mode of delivery, the impact of the therapy on the pregnancy and fetal development as well as breastfeeding. The safety of medical therapy during pregnancy and lactation is a major concern for both pregnant women and their partners as well as for physicians. As a general rule, it can be stated that the benefit of continuing medical therapy in IBD during pregnancy outweighs the potential risks in the vast majority of instances. This article will review recent developments on this topic consistent with the European Crohn's and Colitis Organization guidelines. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available